Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PetVivo Holdings, Inc.PETV · Entity 7591 | Chief Financial Officer | September 16, 2020 | September 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PetVivo Holdings, Inc.
Report date September 16, 2020 · Filed September 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,867 |
Reported balance
After 2020-09-16 transaction · row 1
1 source rowRow 1 · 2020-09-16 · Grant · Acquired 104,867 · Balance 104,867 F1: The Company's Board of Directors granted John Carruth 104,867 shares of restricted stock for exemplary work performed on behalf of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The Company's Board of Directors granted John Carruth 104,867 shares of restricted stock for exemplary work performed on behalf of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2020 Filed Sep 22, 2020 18:33 UTC | PetVivo Holdings, Inc. PETV · Entity 7591 | GrantCommon Stock | 104,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-018163 · ownership.xml · nonDerivative · entry 1 Carruth John Michael · CIK 0001778862 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,867 F1 · price: The Company's Board of Directors granted John Carruth 104,867 shares of restricted stock for exemplary work performed on behalf of the Company. Read SEC document |
| October 31, 2019 Filed Nov 6, 2019 18:55 UTC | PetVivo Holdings, Inc. PETV · Entity 7591 | GrantCommon Stock Warrant · Derivative | 500,000 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001493152-19-016536 · ownership.xml · derivative · entry 1 Carruth John Michael · CIK 0001778862 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,000 Underlying: Common Stock · 500,000 shares Expires 2024-10-31 F1 · price: Granted as compensatory warrants, John Carruth received 500,000 warrants for purchase of shares of PetVivo Holdings, Inc. common stock at a price of $.50 per share. 400,000 warrants are vested quarterly over three years and exercisable for a term of five years from the date of the grant. 100,000 warrants are vested upon achieving performance-based milestones. Read SEC document |
| December 10, 2018 Filed Jun 4, 2019 21:45 UTC | PetVivo Holdings, Inc. PETV · Entity 7591 | GrantCommon Stock Warrant · Derivative | 150,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-19-008698 · ownership.xml · derivative · entry 1 Carruth John Michael · CIK 0001778862 · Acting Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 150,000 shares Expires 2024-12-10 F1 · derivative.underlying_shares: Granted as compensatory warrants, John Carruth received 150,000 warrants for purchase of shares of PetVivo Holdings, Inc. common stock at a price of $.30 per share, vested quarterly for two years, and exercisable for a term of five years from the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.